Clinical Trial

A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)

Study acronym: AB02
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.
Protocol Amendment History 1 change
notable Trial sites expanded: 168 -> 174 locations 2026-06-19
Trial Details
NCT Number NCT07221253
Lead Sponsor AstraZeneca
Conditions Biliary Tract Cancer
Enrollment 1,100 participants
Start Date 2025-12-04
Primary Completion 2029-07-31 (estimated)
Study Completion 2029-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-20